Eidos Therapeutics's Total Assets for the quarter that ended in Sep. 2020 was $161.35 Mil.
During the past 12 months, Eidos Therapeutics's average Total Assets Growth Rate was 0.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 758.50% per year.
During the past 4 years, Eidos Therapeutics's highest 3-Year average Total Assets Growth Rate was 758.50%. The lowest was 758.50%. And the median was 758.50%.
The historical data trend for Eidos Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Eidos Therapeutics's Total Assets for the fiscal year that ended in Dec. 2019 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eidos Therapeutics (NAS:EIDX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Sep. 2020) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Eidos Therapeutics's Asset Turnover for the quarter that ended in Sep. 2020 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Eidos Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Eidos Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Eidos Therapeutics (Eidos Therapeutics) Business Description
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EIDX has been successfully added to your 